s_150324_5a
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- fusion
- YAP1_MAMLD1
- e1_e2
- E2
- umap1_2d
- -7.735467242
- umap2_2d
- 1.12123831
- umap1_3d
- -0.131273409
- umap2_3d
- 3.768381791
- umap3_3d
- 1.681832917
- dataset
- EPN-Heidelberg
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.480
- MYC_TARGETS_V1+0.450
- G2M_CHECKPOINT+0.410
- DNA_REPAIR+0.350
- HYPOXIA+0.310
- TGF_BETA_SIGNALING+0.260
- P53_PATHWAY+0.200
- GLYCOLYSIS+0.160
- UNFOLDED_PROTEIN_RESPONSE+0.150
- MITOTIC_SPINDLE+0.140
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.360
- XENOBIOTIC_METABOLISM-0.340
- IL6_JAK_STAT3_SIGNALING-0.320
- NOTCH_SIGNALING-0.290
- INTERFERON_ALPHA_RESPONSE-0.280
- HEDGEHOG_SIGNALING-0.270
- WNT_BETA_CATENIN_SIGNALING-0.270
- COMPLEMENT-0.250
- BILE_ACID_METABOLISM-0.230
- INFLAMMATORY_RESPONSE-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG889 | — | — | 0.805 |
| 2 | TCGA-DK-A3IM-01A-11R-A20F-07 | — | — | 0.786 |
| 3 | SRR5088878 | — | — | 0.778 |
| 4 | BS_R5SNFB5B | high-grade glioma | — | 0.773 |
| 5 | SRR25043634 | — | — | 0.768 |
| 6 | ERR2278878 | — | — | 0.768 |
| 7 | TCGA-63-A5MH-01A-12R-A27Q-07 | — | cohortSQ1 | 0.764 |
| 8 | SRR12202460 | — | — | 0.763 |
| 9 | ULC0595T_S33 | — | cohortA1 | 0.757 |
| 10 | TCGA-39-5040-01A-21R-2125-07 | — | cohortMD1 | 0.753 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.090 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.010 | Inavolisib | — uncovered |